NL-OMON48189
Completed
Not Applicable
An open*label, randomized, 3*period crossover study to determine the relative bioavailability of ASN120290 from a film*coated tablet given under fasted and fed conditions as compared to a capsule given under fasted conditions in healthy subjects - ASN120290-103-EU (CS0320)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Asceneuron SA
- Enrollment
- 15
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Deemed healthy on the basis of medical history, physical examination, ECG, vital signs, and laboratory tests of blood and urine. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if, in the opinion of the Investigator, the finding is (a) unlikely to introduce additional risk to the subject, (b) will not interfere with study procedures or confound study results and (c) is not evaluated as clinically significant.;Subjects must be between 18 and 75 years of age, inclusive, at Screening.;Male healthy volunteer, or women of non\*childbearing potential (i.e. postmenopausal \[the last spontaneous menstrual period was at least 12 months ago, and FSH at Screening confirms post\*menopausal status (FSH \*30 U/L)], or has no uterus, ovaries or fallopian tubes or has their fallopian tubes tied).;For more inclusion criteria please refer to the protocol.
Exclusion Criteria
- •Women who are pregnant, or lactating, or of child\-bearing potential.;History of epilepsy or seizures, other than benign febrile convulsions in childhood.;Positive result for suicidal ideation or behavior using the C\*SSRS at Screening.;For more exclusion criteria please refer to the protocol.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Relative bioavailability study of marketed and lower dose ambrisentan in healthy adult participantsEUCTR2019-001699-12-GBGlaxoSmithKline Research and Development Ltd24
Completed
Not Applicable
Comparison between the SpirofyTM Spirometer newly developed by Cipla Ltd. with an existing Spirometer (Vitalograph Alpha Touch Spirometer) in healthy, asthmatic and COPD SubjectsHealth Condition 1: J449- Chronic obstructive pulmonary disease, unspecifiedHealth Condition 2: J459- Other and unspecified asthmaCTRI/2021/09/036492Cipla Limited90
Not yet recruiting
Not Applicable
An investigator initiated study to study how well does a newly developed spirometer by Cipla Ltd. work as compared to the spirometer already available in the market.CTRI/2019/08/020738Chest Research Foundation
Completed
Phase 1
A study to investigate the safety, tolerability and concentration in the blood of nicotine compared between different types of nicotine replacement therapies (NRTs)Smoking cessation and nicotine replacement therapies (NRT)Not ApplicableISRCTN17715270Ventus Medical Limited24
Active, not recruiting
Not Applicable
An Open-label, Randomised, Three -Way, Cross-Over Study to Assess the Pharmacokinetics, Safety and Tolerability of Two Formulations of RBP-6300 10mg in Healthy Volunteers under a Naltrexone Block in the Presence and Absence of Food.Maintenance/substitution agent for the treatment of opioid dependence.MedDRA version: 16.0Level: LLTClassification code 10012346Term: Dependence on opiatesSystem Organ Class: 100000004873Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2012-002408-42-GBReckitt Benckiser Pharmaceuticals Inc.